The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 08, 2006
Filed:
Jun. 25, 2003
Upul K. Bandarage, Lexington, MA (US);
Richard A. Earl, Westford, MA (US);
Maiko Ezawa, Acton, MA (US);
Xinqin Fang, Lexington, MA (US);
David S. Garvey, Dover, MA (US);
Subhash P. Khanapure, Clinton, MA (US);
Ramani R. Ranatunga, Lexington, MA (US);
Stewart K. Richardson, Tolland, CT (US);
Joseph D. Schroeder, Minneapolis, MA (US);
Cheri A. Stevenson, Haverhill, MA (US);
Shiow-jyi Wey, Woburn, MA (US);
Upul K. Bandarage, Lexington, MA (US);
Richard A. Earl, Westford, MA (US);
Maiko Ezawa, Acton, MA (US);
Xinqin Fang, Lexington, MA (US);
David S. Garvey, Dover, MA (US);
Subhash P. Khanapure, Clinton, MA (US);
Ramani R. Ranatunga, Lexington, MA (US);
Stewart K. Richardson, Tolland, CT (US);
Joseph D. Schroeder, Minneapolis, MA (US);
Cheri A. Stevenson, Haverhill, MA (US);
Shiow-Jyi Wey, Woburn, MA (US);
Nitromed, Inc., Lexington, MA (US);
Abstract
The invention describes novel cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one COX-2 selective inhibitor, optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and/or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal and/or respiratory toxicity; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.